Searching the Crystal Ball for Tailored GLP‐1 Receptor Agonists Treatment in Type 2 Diabetes and Obesity
- 14 December 2024
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 41 (1) , e70017
Abstract
Background: Glucagon‐like peptide 1 receptor agonists (RA) are novel agents used in the management of type 2 diabetes (T2D) and obesity. Although highly effective, the response to treatment may vary significantly among patients.Objective: This perspective review aims to summarise the current knowledge about markers of poor or good response to GLP‐1 RA, highlighting the possibility of tailoring treatment strategies and reducing costs associated with T2D and obesity treatment.Methods: A comprehensive literature search was conducted using PubMed, NCBI, and Scopus databases, focussing on studies published between 2016 and 2024 that evaluated factors influencing treatment outcomes with GLP‐1 RA.Results: Several markers, including baseline HbA1c levels, ghrelin and glucose‐dependent insulinotropic polypeptide (GIP) levels, specific gut microbiome composition, b‐cell function, and genetic markers, were identified as factors associated with treatment response.Conclusion: Understanding predictive markers of response to therapy can enhance precision‐based medicine for the selection of patients eligible for GLP‐1 RA, improving clinical outcomes and optimising diabetes management.Keywords
This publication has 11 references indexed in Scilit:
- The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort studyFrontiers in Endocrinology, 2024
- Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP‐1RA therapy in adolescents with severe obesityPediatric Obesity, 2024
- Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesmedRxiv, 2023
- Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or ObesityJAMA Network Open, 2022
- Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetesCell Reports Medicine, 2021
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-artMolecular Metabolism, 2021
- Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and ObesityJournal of Diabetes Research, 2019
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- Cardiovascular Effects of Glucagonlike peptide–1 AgonistsThe American Journal of Cardiology, 2011
- Insulin resistance and obesityClinics in Dermatology, 2004